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Background
The HIV vaccine regimen showing partial efficacy in the
RV 144 study included a canarypox-vectored vaccine
(ALVAC). The ongoing HIV vaccine efficacy trial, HVTN
505, involves two gene-based vaccines developed by VRC/
NIAID/NIH: plasmid DNA and adenoviral-vectored
vaccines. The “NIH Guidelines for Research Involving
Recombinant DNA Molecules,” established in 1976, have
evolved over time. Current NIH policy is that every clinical
trial of rDNA vaccines must have IBC reviews. The pri-
mary role of the IBC is to assess risk to public health and
the environment.
Methods
The NIAID Barriers to Clinical Research project identi-
fied repetitive IBC review of gene-based vaccines as a
barrier. For example, in the last 10 years >100 local IBC
reviews have been conducted for the VRC HIV vaccines.
IBC reviews for ALVAC vaccines remain a requirement
for NIH funding despite completion of a Phase III clini-
cal trial, >20 years of human experience with ALVAC
vaccines and widespread community-based use of
USDA-approved canarypox-vectored veterinary vaccines,
which have not indicated a risk to public health or the
environment.
Results
The NIAID policy change proposal has been considered
by a Recombinant DNA Advisory Committee (RAC)
working group. Policy change options were discussed at
the September 2011, December 2011 and March 2012
RAC meetings. The RAC proposal will be published in
the Federal Register for public comments.
Conclusion
Repetitive IBC reviews of rDNA vaccine clinical trials
divert time and attention of IBC expertise from truly novel
agents and incur a cost to NIH with no added safety bene-
fit. NIAID proposes that IBC review is no longer needed
for clinical trials of non-transmissible rDNA vaccines
because there are no unique biosafety concerns for this
class of vaccines based on their recombinant DNA nature.
The IBC specific roles are not applicable for rDNA vaccine
protocols and are fulfilled through other regulatory over-
sight including the FDA.
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